Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.50 |
| ▸ | DUT | P33316 | 1/20 | 0.48 |
| ▸ | TK2 | O00142 | 4/20 | 0.46 |
| ▸ | SLC6A1 | P30531 | 3/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | PAM | P19021 | 1/20 | 0.36 |
| ▸ | TK1 | P04183 | 1/20 | 0.35 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26305210 | 1.00 | KIF11 (0.50) | KIF11DUTTK2SLC6A1ALOX15 | |
| SCHEMBL7926252 | 0.98 | KIF11 (0.52) | KIF11DUTTK2SLC6A1ALOX15 | |
| SCHEMBL18095510 | 0.94 | KIF11 (0.45) | KIF11DUTTK2SLC6A1HRH4 | |
| SCHEMBL6839724 | 0.87 | SLC6A11 (0.50) | KIF11DUTSLC6A1KMT2ASLC6A11 | |
| SCHEMBL26176885 | 0.85 | KIF11 (0.65) | KIF11DUTTK2SLC6A1ALOX15 | |
| SCHEMBL26176899 | 0.85 | KIF11 (0.65) | KIF11DUTTK2SLC6A1ALOX15 | |
| SCHEMBL26176905 | 0.85 | KIF11 (0.65) | KIF11DUTTK2SLC6A1ALOX15 | |
| SCHEMBL31430932 | 0.85 | KIF11 (0.65) | KIF11DUTTK2SLC6A1ALOX15 | |
| SCHEMBL26176887 | 0.85 | KIF11 (0.65) | KIF11DUTTK2SLC6A1ALOX15 | |
| SCHEMBL26176886 | 0.85 | KIF11 (0.65) | KIF11DUTTK2SLC6A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919653-B2 | Method of inhibiting nonspecific interaction between molecules on solid phase support | REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. (JP) | 2011-04-05 | — | — | US | disclosed |
| EP-2157429-A2 | Method of inhibiting nonspecific interaction between molecules on solid phase support | Reverse Proteomics Research Institute Co., Ltd (JP) | 2010-02-24 | — | — | EP | disclosed |
| US-20080176341-A1 | Method for Suppressing Intermolecular Nonspecific Interaction and for Intensifying Intermolecular Specific Interaction on Metal Surface | REVERSE PROTEMICS RESEARCH INSTITUTE CO., LTD. (JP) | 2008-07-24 | — | — | US | disclosed |
| US-20060177943-A1 | Method of inhibiting nonspecific interaction between molecules on solid phase support | REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. (JP) | 2006-08-10 | — | — | US | disclosed |
| EP-1553412-A1 | METHOD OF INHIBITING NONSPECIFIC INTERACTION BETWEEN MOLECULES ON SOLID PHASE SUPPORT | Reverse Proteomics Research Institute Co., Ltd (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060177943-A1 | Method of inhibiting nonspecific interaction between molecules on solid phase support | CD2BP2, CD14, SPR | KIF11 2893/4885DUT 3616/4885TK2 2784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.